Running a HRMY wheel strategy lets you generate consistent premium income on Harmony Biosciences Holdings Inc while setting your own entry and exit prices on the underlying. Harmony Biosciences Holdings Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own HRMY, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best HRMY wheel strategy setups in real time.
The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on HRMY, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable HRMY wheel from a losing one.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the HRMY wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your HRMY wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.
